Pure Global

A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) - Trial 2019-001123-13

Access comprehensive clinical trial information for 2019-001123-13 through Pure Global AI's free database. This phase not specified trial is sponsored by Verastem, Inc. and is currently No longer available. The study focuses on Peripheral T-cell Lymphoma.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
2019-001123-13
No longer available
Trial Details
EU Clinical Trials Register • 2019-001123-13
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Study Focus

Sponsor & Location

Verastem, Inc.

Timeline & Enrollment

N/A

N/A

N/A

Primary Outcome

1. Primary leukemic PTCL subtypes (i.e., T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, Adult T-cell leukemia/lymphoma and Aggressive NK-cell leukemia) or transformed mycosis fungoides

ICD-10 Classifications

Peripheral T-cell lymphoma, not elsewhere classified
Cutaneous T-cell lymphoma, unspecified
Mature T/NK-cell lymphomas
Angioimmunoblastic T-cell lymphoma
Other mature T/NK-cell lymphomas

Data Source

EU Clinical Trials Register

2019-001123-13

Non-Device Trial